These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 18195683)

  • 1. High incidence of graft failure in unrelated cord blood transplantation using a reduced-intensity preparative regimen consisting of fludarabine and melphalan.
    Narimatsu H; Watanabe M; Kohno A; Sugimoto K; Kuwatsuka Y; Uchida T; Murata M; Miyamura K; Morishita Y;
    Bone Marrow Transplant; 2008 Apr; 41(8):753-6. PubMed ID: 18195683
    [No Abstract]   [Full Text] [Related]  

  • 2. The Addition of Low-Dose Total Body Irradiation to Fludarabine and Melphalan Conditioning in Haplocord Transplantation for High-Risk Hematological Malignancies.
    Choe HK; Gergis U; Mayer SA; Nagar H; Phillips AA; Shore TB; Smith MJ; van Besien K
    Transplantation; 2017 Jan; 101(1):e34-e38. PubMed ID: 27764032
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Successful engraftment of mismatched unrelated cord blood transplantation following reduced intensity preparative regimen using fludarabine and busulfan.
    Komatsu T; Narimatsu H; Yoshimi A; Kurita N; Kusakabe M; Hori A; Murashige N; Matsumura T; Kobayashi K; Yuji K; Tanaka Y; Kami M
    Ann Hematol; 2007 Jan; 86(1):49-54. PubMed ID: 17036221
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Successful second cord blood transplantation using fludarabine and cyclophosphamide as a preparative regimen for graft rejection following reduced-intensity cord blood transplantation.
    Mizutani E; Narimatsu H; Murata M; Tomita A; Kiyoi H; Naoe T
    Bone Marrow Transplant; 2007 Jul; 40(1):85-7. PubMed ID: 17450178
    [No Abstract]   [Full Text] [Related]  

  • 5. Reduced-intensity conditioning allogeneic hematopoietic cell transplantation using oral fludarabine as part of the conditioning regimen.
    Delgado J; Marco A; Moreno E; Piñana J; Valcarcel D; Martino R; Briones J; Sureda A; Brunet S; Sierra J
    Cytotherapy; 2009; 11(3):356-61. PubMed ID: 19148841
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treosulfan-based conditioning regimen for allogeneic haematopoietic stem cell transplantation in patients with thalassaemia major.
    Bernardo ME; Zecca M; Piras E; Vacca A; Giorgiani G; Cugno C; Caocci G; Comoli P; Mastronuzzi A; Merli P; La Nasa G; Locatelli F
    Br J Haematol; 2008 Nov; 143(4):548-51. PubMed ID: 18986389
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A conditioning regimen of busulfan, fludarabine, and melphalan for allogeneic stem cell transplantation in children with juvenile myelomonocytic leukemia.
    Yabe M; Sako M; Yabe H; Osugi Y; Kurosawa H; Nara T; Tokuyama M; Adachi S; Kobayashi C; Yanagimachi M; Ohtsuka Y; Nakazawa Y; Ogawa C; Manabe A; Kojima S; Nakahata T;
    Pediatr Transplant; 2008 Dec; 12(8):862-7. PubMed ID: 18397212
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fludarabine allows dose reduction for total body irradiation in pediatric hematopoietic stem cell transplantation.
    Kornguth DG; Mahajan A; Woo S; Chan KW; Antolak J; Ha CS
    Int J Radiat Oncol Biol Phys; 2007 Jul; 68(4):1140-4. PubMed ID: 17379444
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hemophagocytosis during fludarabine-based SCT for systemic juvenile idiopathic arthritis.
    Ferreira RA; Vastert SJ; Abinun M; Foster HE; Modesto C; Olivé T; Kuis W; Wulffraat NM
    Bone Marrow Transplant; 2006 Aug; 38(3):249-51. PubMed ID: 16770315
    [No Abstract]   [Full Text] [Related]  

  • 10. Regimen-related mucosal injury of the gut increased the incidence of CMV disease after allogeneic bone marrow transplantation.
    Shigematsu A; Yasumoto A; Yamamoto S; Sugita J; Kondo T; Onozawa M; Kahata K; Endo T; Ota S; Sato N; Takahata M; Okada K; Tanaka J; Hashino S; Nishio M; Koike T; Asaka M; Imamura M
    Biol Blood Marrow Transplant; 2009 Jun; 15(6):679-85. PubMed ID: 19450752
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Engraftment syndrome after hematopoietic stem cell transplantation in multiple myeloma.
    Katzel JA; Mazumder A; Jagannath S; Vesole DH
    Clin Lymphoma Myeloma; 2006 Sep; 7(2):151. PubMed ID: 17026829
    [No Abstract]   [Full Text] [Related]  

  • 12. Unrelated umbilical cord blood transplantation using a TBI/FLAG conditioning regimen for adults with hematologic malignancies.
    Okada M; Fujimori Y; Misawa M; Kai S; Nakajima T; Okikawa Y; Satake A; Itoi H; Takatsuka H; Itsukuma T; Nishioka K; Tamaki H; Ikegame K; Hara H; Ogawa H
    Biol Blood Marrow Transplant; 2008 Aug; 14(8):896-903. PubMed ID: 18640573
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Successful engraftment of cord blood following a one-day reduced-intensity conditioning regimen in two patients suffering primary graft failure and sepsis.
    Shimizu I; Kobayashi H; Nasu K; Otsuki F; Ueki T; Sumi M; Ueno M; Ichikawa N; Nakao S
    Bone Marrow Transplant; 2009 Nov; 44(9):617-8. PubMed ID: 19349955
    [No Abstract]   [Full Text] [Related]  

  • 14. Successful engraftment by second cord blood transplantation with reduced-intensity conditioning after graft rejection due to hemophagocytic syndrome following initial CBT.
    Tanaka H; Ohwada C; Sakaida E; Takeda Y; Abe D; Oda K; Ozawa S; Shimizu N; Masuda S; Cho R; Nishimura M; Saito Y; Nakaseko C
    Bone Marrow Transplant; 2007 Nov; 40(10):995-6. PubMed ID: 17768388
    [No Abstract]   [Full Text] [Related]  

  • 15. Oral mucositis in myeloma patients undergoing melphalan-based autologous stem cell transplantation: incidence, risk factors and a severity predictive model.
    Grazziutti ML; Dong L; Miceli MH; Krishna SG; Kiwan E; Syed N; Fassas A; van Rhee F; Klaus H; Barlogie B; Anaissie EJ
    Bone Marrow Transplant; 2006 Oct; 38(7):501-6. PubMed ID: 16980998
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Costs of hematopoietic cell transplantation: comparison of umbilical cord blood and matched related donor transplantation and the impact of posttransplant complications.
    Majhail NS; Mothukuri JM; Brunstein CG; Weisdorf DJ
    Biol Blood Marrow Transplant; 2009 May; 15(5):564-73. PubMed ID: 19361748
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Busulfan, fludarabine, and alemtuzumab conditioning and unrelated cord blood transplantation in children with sickle cell disease.
    Radhakrishnan K; Bhatia M; Geyer MB; Del Toro G; Jin Z; Baker C; Harrison L; Morris E; Baxter-Lowe LA; Cairo MS
    Biol Blood Marrow Transplant; 2013 Apr; 19(4):676-7. PubMed ID: 23403308
    [No Abstract]   [Full Text] [Related]  

  • 18. Successful reduced intensity allogeneic stem cell transplantation for systemic AL amyloidosis.
    Imamura T; Ogata M; Kohno K; Tomo T; Ohtsuka E; Kikuchi H; Kadota J
    Am J Hematol; 2006 Apr; 81(4):281-3. PubMed ID: 16550508
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mucositis not neutropenia determines bacteremia among hematopoietic stem cell transplant recipients.
    Herbers AH; de Haan AF; van der Velden WJ; Donnelly JP; Blijlevens NM
    Transpl Infect Dis; 2014 Apr; 16(2):279-85. PubMed ID: 24621081
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chimerism status after unrelated donor bone marrow transplantation with fludarabine-melphalan conditioning is affected by the melphalan dose and is predictive of relapse.
    Imahashi N; Ohashi H; Terakura S; Miyao K; Sakemura R; Kato T; Sawa M; Yokohata E; Kurahashi S; Ozawa Y; Nishida T; Kiyoi H; Watamoto K; Kohno A; Kasai M; Kato C; Iida H; Naoe T; Miyamura K; Murata M;
    Ann Hematol; 2015 Jul; 94(7):1139-48. PubMed ID: 25680895
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.